JDQ443: Clinical Trials

8 trials of JDQ443, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 active not recruiting, 2 terminated, 1 completed, 1 withdrawn. 6 Phase 2, 4 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 26Active not recruiting 4, Terminated 1, Withdrawn 1
Phase 14Active not recruiting 2, Completed 1, Terminated 1
Phase 31Terminated 1

Follow JDQ443: new trials by email Literature Review of JDQ443 trials Research Report on JDQ443

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
Opnurasib, TNO155, trametinib - Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation
Phase 1 / Phase 2Active not recruitingNovartis Pharmaceuticals252026-06-082026-10-23
JDQ443 for KRAS G12C NSCLC Brain Metastases
JDQ443 - Non Small Cell Lung Cancer Metastatic, Brain Metastases, Adult
Phase 2WithdrawnMaastricht University Medical Center2024-04-152024-05-29
Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer
JDQ443 - NSCLC
Phase 2Active not recruitingCanadian Cancer Trials Group42023-09-152026-10-26
Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.
JDQ443 - Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Phase 2Active not recruitingNovartis Pharmaceuticals952022-12-062026-10-08
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
JDQ443, trametinib, Ribociclib - KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung
Phase 1 / Phase 2TerminatedNovartis Pharmaceuticals742022-10-242026-10-21
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
JDQ443, docetaxel - Non-Small Cell Lung Cancer
Phase 3TerminatedNovartis Pharmaceuticals952022-06-152026-11-06
A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.
JDQ443 - Small Cell Lung Carcinoma
Phase 1CompletedNovartis Pharmaceuticals332022-05-032025-10-10
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
JDQ443, TNO155, tislelizumab - KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung
Phase 1 / Phase 2Active not recruitingNovartis Pharmaceuticals3442021-02-242026-10-19

Conditions studied

Carcinoma, Non-Small-Cell Lung (5)  ·  Colorectal Neoplasms (3)  ·  Lung Neoplasms (3)  ·  Brain Neoplasms (1)  ·  Neoplasm Metastasis (1)  ·  Small Cell Lung Carcinoma (1)

Sponsors

Novartis Pharmaceuticals (6)  ·  Canadian Cancer Trials Group (1)  ·  Maastricht University Medical Center (1)

Countries

Italy (5)  ·  Spain (5)  ·  United States (5)  ·  Belgium (4)  ·  Canada (4)  ·  China (4)  ·  France (4)  ·  South Korea (4)  ·  Germany (3)  ·  Malaysia (3)  ·  Argentina (2)  ·  Australia (2)  ·  Denmark (2)  ·  Greece (2)  ·  Hong Kong (2)

Top investigators

Jonathan Spicer (1)  ·  Lizza Hendriks, MD, PhD (1)  ·  Normand Blais (1)

Results publications

PMID 36399068

NIH funding

2023 (3), 2025 (1)